Section 2: Antimicrobial Stewardship Operations (Faculty)
The content within Section 2 are directed at providing the steward - in - training with knowledge, skills, and resources to assess the current and ever-changing state of one’s Antimicrobial Stewardship Program(ASP). The mini-lectures within the eLearning will introduce the concept of the Antimicrobial Stewardship Toolbelt. The Application Activities and Workbooks are focused on having the learner apply the Toolbelt to their local institution. It will also help them to learn about the importance of prioritization of initiatives and daily tasks.
As the faculty or stewardship champion leading this effort, you can decide how the content is distributed and presented to your stewards- in- training.
For Stewards - in - Training:
The fellow/trainee can watch the eLearning on their own, followed by a debrief between fellow and faculty.
To present in a classroom or small group setting, you can open the eLearning and let it talk for you, controlling the slides and the pace. You can also disable the audio and narrate the eLearning yourself.
Program Directors, Antimicrobial Stewardship Faculty Champions, and additional Faculty responsible for leading and implementing the Curriculum.
Upon completion of this section, stewards- in- training will be able to:
- Analyze local institutional data (e.g. antimicrobial use and resistance patterns) to identify impactful local stewardship initiatives
- Demonstrate an understanding of where to focus on changing practice and how to identify “low hanging fruit”
- Prioritize antimicrobial stewardship initiatives (e.g. electronic alerts, restricted antimicrobial approval) into a productive, feasible daily workflow designed to meet local institutional needs
- Identify methods to use EHS to support AS activities
- Manage non-formulary drug requests (P & T considerations)
- Describe systematic approaches to improving antimicrobial use in the major “infection syndromes” where antimicrobials are over- and misused
- Create and update local treatment guidelines using local antibiogram data
AS Curriculum Workgroup COI Summary Reviewed April 2017 by Rachel Simmons, MD No conflicts found
|Name||Individual's Role in Activity||Name of Commercial Interest||Nature of Relationship|
|Abbo, Lillian||Workgroup member||Pfizer Brazil||Honoraria|
|Advani, Sonali||Workgroup member||Nabriva Therapeutics||Advisory/Consultant Role|
|Amstrong, Wendy||Workgroup member||None|
|Barsoumian, Alice||Workgroup member||None|
|Beeler, Cole||Workgroup member||None|
|Bystritsky, Rachel||Workgroup member||None|
|Cherabuddi, Kartik||Workgroup member||Gatorade||Start - up Research Fund|
|NIH (Medimmune)||Research Grant|
|Cohen, Seth||Workgroup member||None|
|Hamilton, Keith||Workgroup member||None|
|Ince, Dilek||Workgroup member||Ansun Pharma||Research Grant|
|Justo, Julie Ann||Workgroup member||None|
|Luther, Vera||Workgroup member||None|
|Lynch, John||Workgroup member||Astellas Pharmaceuticals, Juno Therapeutics||Advisory/Consultant Role|
|Nori, Priya||Workgroup member||None|
|Ohl, Christopher||Workgroup member||Paratek, Bayer, Cempra Pharmaceuticals||Advisory/Consultant Role|
|Patel, Payal||Workgroup member||None|
|Pottinger, Paul||Workgroup member||McGraw Hill, Elsevier||Honoraria|
|Schwartz, Brian||Workgroup member||None|
|Spicer, Jennifer||Workgroup member||None|
|Stack, Conor||Workgroup member||None|
|Zhou, Yuan||Workgroup member||None|